Editorial: Benefit of Direct-Acting Antiviral Therapy for Cryoglobulinemia due to Hepatitis C Infection

Paul Martin, Fabizio Fabrizi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Extrahepatic consequences of hepatitis C infection are increasingly recognized as a source of additional morbidity distinct from the consequences of liver disease. Among the best characterized of these is mixed cryoglobulinemia, which can lead to a variety of disorders, including vasculitis and glomerulonephritis. In general, the results of antiviral therapy in the interferon era had been disappointing, but now with new all-oral regimens response rates are substantially better. However, even with successful clearance of the virus symptomatic response can lag.

Original languageEnglish
Pages (from-to)1309-1310
Number of pages2
JournalAmerican Journal of Gastroenterology
Volume112
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Cryoglobulinemia
Hepatitis C
Glomerulonephritis
Vasculitis
Interferons
Antiviral Agents
Liver Diseases
Viruses
Morbidity
Infection
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Editorial : Benefit of Direct-Acting Antiviral Therapy for Cryoglobulinemia due to Hepatitis C Infection. / Martin, Paul; Fabrizi, Fabizio.

In: American Journal of Gastroenterology, Vol. 112, No. 8, 01.08.2017, p. 1309-1310.

Research output: Contribution to journalReview article

@article{1f362e36bfff47f89416966b1895f381,
title = "Editorial: Benefit of Direct-Acting Antiviral Therapy for Cryoglobulinemia due to Hepatitis C Infection",
abstract = "Extrahepatic consequences of hepatitis C infection are increasingly recognized as a source of additional morbidity distinct from the consequences of liver disease. Among the best characterized of these is mixed cryoglobulinemia, which can lead to a variety of disorders, including vasculitis and glomerulonephritis. In general, the results of antiviral therapy in the interferon era had been disappointing, but now with new all-oral regimens response rates are substantially better. However, even with successful clearance of the virus symptomatic response can lag.",
author = "Paul Martin and Fabizio Fabrizi",
year = "2017",
month = "8",
day = "1",
doi = "10.1038/ajg.2017.199",
language = "English",
volume = "112",
pages = "1309--1310",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Editorial

T2 - Benefit of Direct-Acting Antiviral Therapy for Cryoglobulinemia due to Hepatitis C Infection

AU - Martin, Paul

AU - Fabrizi, Fabizio

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Extrahepatic consequences of hepatitis C infection are increasingly recognized as a source of additional morbidity distinct from the consequences of liver disease. Among the best characterized of these is mixed cryoglobulinemia, which can lead to a variety of disorders, including vasculitis and glomerulonephritis. In general, the results of antiviral therapy in the interferon era had been disappointing, but now with new all-oral regimens response rates are substantially better. However, even with successful clearance of the virus symptomatic response can lag.

AB - Extrahepatic consequences of hepatitis C infection are increasingly recognized as a source of additional morbidity distinct from the consequences of liver disease. Among the best characterized of these is mixed cryoglobulinemia, which can lead to a variety of disorders, including vasculitis and glomerulonephritis. In general, the results of antiviral therapy in the interferon era had been disappointing, but now with new all-oral regimens response rates are substantially better. However, even with successful clearance of the virus symptomatic response can lag.

UR - http://www.scopus.com/inward/record.url?scp=85026852019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026852019&partnerID=8YFLogxK

U2 - 10.1038/ajg.2017.199

DO - 10.1038/ajg.2017.199

M3 - Review article

AN - SCOPUS:85026852019

VL - 112

SP - 1309

EP - 1310

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -